COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF
申请人:Zischinsky Gunter
公开号:US20090104116A1
公开(公告)日:2009-04-23
The present invention is related to a compound of formula (I), wherein A is a nonaromatic heterocyclic ring, Ar is either absent or phenylene; Ψ is a radical of formula (II), R
2
is a hydrophobic moiety; and G is a radical containing one or more moieties selected from the group consisting of NH, OH and a basic moiety. The compounds are inhibitors of integrins, especially antagonists of the fibronectin receptor alpha5beta1, useful as anti-angiogenic agents.
HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF
申请人:Zischinsky Gunther
公开号:US20090203745A1
公开(公告)日:2009-08-13
The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or 3 heteroatoms selected from the group comprising N, O and S; Z is a linker and Ψ is a radical of formula (II) and their use for the inhibition of integrin.
USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES
申请人:Boehringer Ingelheim International GmbH
公开号:EP2346507A1
公开(公告)日:2011-07-27
9-[4-(3-CHLOR-2-FLUOR-PHENYLAMINO)-7-METHOXY-CHINAZOLIN-6- YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDECAN-5-ON DIMALEAT, DESSEN VERWENDUNG ALS ARZNEIMITTEL UND DESSEN HERSTELLUNG
申请人:Boehringer Ingelheim International GmbH
公开号:EP2670736A1
公开(公告)日:2013-12-11
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
申请人:Merck Sharp & Dohme Corp.
公开号:US20170275298A1
公开(公告)日:2017-09-28
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.